Anaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy. (Q36158713)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15948671%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

review article

1 reference

title

Anaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15948671%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15948671%20AND%20SRC:MED&resulttype=core&format=json

Carlo Gambacorti-Passerini

12 January 2020

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15948671%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Lorena Passoni

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15948671%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

author name string

A M L Coluccia

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15948671%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

R H Gunby

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15948671%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

L Scapozza

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15948671%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

language of work or name

English

0 references

publication date

1 June 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15948671%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Therapeutic Targets

12 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15948671%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15948671%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15948671%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

page(s)

515-532

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15948671%20AND%20SRC:MED&resulttype=core&format=json

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

12 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Anaplastic large cell lymphoma: a clinicopathologic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children's Cancer Study Group chemotherapy regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Early molecular detection of central nervous system relapse in a child with systemic anaplastic large cell lymphoma: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

ALK+, CD30-, CD20- large B-cell lymphoma containing anaplastic lymphoma kinase (ALK) fused to clathrin heavy chain gene (CLTC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Identification and characterization of DAlk: a novel Drosophila melanogaster RTK which drives ERK activation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Anti-apoptotic signaling of pleiotrophin through its receptor, anaplastic lymphoma kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Assessment of t(2;5)(p23;q35) translocation and variants in pediatric ALK+ anaplastic large cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Heterogeneity of genomic breakpoints in MSN-ALK translocations in anaplastic large cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Translocations involving anaplastic lymphoma kinase (ALK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Inhibition of tyrosine kinase activity induces caspase-dependent apoptosis in anaplastic large cell lymphoma with NPM-ALK (p80) fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

The oncogenic fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) induces two distinct malignant phenotypes in a murine retroviral transplantation model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Spontaneous vitiligo in an animal model for human melanoma: role of tumor-specific CD8+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Progress on new vaccine strategies for the immunotherapy and prevention of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Vaccination with T cell-defined antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

The makings of a tumor rejection antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

A listing of human tumor antigens recognized by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

A listing of human tumor antigens recognized by T cells: March 2004 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

The immunobiology of cancer immunosurveillance and immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Stable suppression of tumorigenicity by virus-mediated RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

21 January 2018

Ribozyme therapeutics

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Approaches for the sequence-specific knockdown of mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Ribozyme- and deoxyribozyme-strategies for medical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Hammerhead ribozyme-mediated cleavage of the fusion transcript NPM-ALK associated with anaplastic large-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

siRNA therapeutics: big potential from small RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Short interfering RNAs as a tool for cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Design and evaluation of chemically synthesized siRNA targeting the NPM-ALK fusion site in anaplastic large cell lymphoma (ALCL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Protein kinase inhibitors: insights into drug design from structure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Targeted therapies and non-small cell lung cancer: methodological and conceptual challenge for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Imatinib as a paradigm of targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Protein tyrosine kinases: autoregulation and small-molecule inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

The protein kinase complement of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Staurosporine-induced conformational changes of cAMP-dependent protein kinase catalytic subunit explain inhibitory potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Preclinical and clinical development of cyclin-dependent kinase modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

The 'peptoid' approach to the design of non-peptide, small molecule agonists and antagonists of neuropeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

HA14-1 selectively induces apoptosis in Bcl-2-overexpressing leukemia/lymphoma cells, and enhances cytarabine-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Anatomy of hot spots in protein interfaces

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

A hot spot of binding energy in a hormone-receptor interface

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Small molecule antagonists of proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Identification of NPM-ALK interacting proteins by tandem mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Hsp90, not Grp94, regulates the intracellular trafficking and stability of nascent ErbB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

The Hsp90 chaperone complex as a novel target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Hsp90: an emerging target for breast cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Hsp90 as a therapeutic target in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Role of phosphatidylinositol-3-kinase in insulin receptor signaling: studies with inhibitor, LY294002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Molecular modeling studies of the Akt PH domain and its interaction with phosphoinositides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Activation of the PI3K/Akt pathway and chemotherapeutic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

NPM/ALK downregulates p27Kip1 in a PI-3K-dependent manner.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Mechanisms of resistance to rapamycins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

STAT proteins: novel molecular targets for cancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Of JAKs, STATs, blind watchmakers, jeeps and trains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Bcl-XL down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

The tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intracellular domain of the surface receptor CD30 but is not activated by CD30 stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

High-level expression of BCL3 differentiates t(2;5)(p23;q35)-positive anaplastic large cell lymphoma from Hodgkin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

BCL-3 overexpression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF-kappaB activation in anaplastic large cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Characterization of the CD30L binding domain on the human CD30 molecule using anti-CD30 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Large cell non-Hodgkin lymphoma of childhood: Analysis of 78 consecutive patients enrolled in 2 consecutive protocols at the Memorial Sloan-Kettering Cancer Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

A single-centre study of treatment outcomes and survival in 120 patients with peripheral T-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Anaplastic large cell lymphoma in Japanese children: retrospective analysis of 34 patients diagnosed at the National Research Institute for Child Health and Development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

STI571 as a targeted therapy for CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Overexpression of NPM–ALK induces different types of malignant lymphomas in IL-9 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.515

21 January 2018

Identifiers

DOI

10.1517/14728222.9.3.515

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15948671%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

1 reference